Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 190

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 190
---
 97.4 Other long-term liabilities2.2 41.3 Total liabilities326.5 363.3 Commitments and contingenciesStockholders’ equity:Common stock, $0.01 par value, 91.3 and 89.9 shares outstanding at December 31, 2024 and 2023, respectively0.9 0.9 Additional paid-in capital1,457.8 1,415.5 Accumulated other comprehensive loss(0.8)(3.7)Accumulated deficit(756.8)(629.5)Total stockholders' equity701.1 783.2 Total liabilities and stockholders’ equity$1,027.6 $1,146.5 

See accompanying notes to consolidated financial statements.

77

Table of Contents

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Consolidated Statements of Operations

(in millions, except per share amounts)

Years Ended December 31,202420232022Revenue$837.6 $753.2 $678.4 Cost of revenue252.2 236.2 202.0 Gross profit585.4 517.0 476.4 Operating expenses:Research and development expense113.4 88.7 85.4 Sales and marketing expense284.1 289.2 266.8 General and administrative expense275.9 283.7 247.9 Legal settlements(21.3)112.8 — Goodwill and long-lived asset impairment charges56.8 — 16.9 Total operating expenses708.9 774.4 617.0 Operating loss(123.5)(257.4)(140.6)Other income (expense):Interest income1.7 2.5 2.6 Interest expense(2.8)(2.9)(3.2)Other1.1 (4.4)0.6 Total other expense— (4.8)— Loss before income tax(123.5)(262.2)(140.6)Income tax expense (benefit)3.8 1.1 (28.6)Net loss$(127.3)$(263.3)$(112.0)Net loss per share:Basic and diluted$(1.41)$(3.18)$(1.39)Weighted average shares